ketoconazole has been researched along with Ovarian Neoplasms in 8 studies
1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.
Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ketoconazole has shown activity in advanced GCT in clinical and in vitro studies." | 3.30 | Open-label phase II clinical trial of ketoconazole as CYP17 inhibitor in metastatic or advanced non-resectable granulosa cell ovarian tumors: the GREKO (GRanulosa Et KetOconazole) trial, GETHI 2011-03. ( Bover, I; Cueva, J; de Castro, IP; Garcia-Casado, Z; Garcia-Donas, J; Garcia-Martinez, E; Garrigos, L; Grande, E; Guerra, E; Hurtado, A; Lainez, N; Lopez-Guerrero, JA; Navarro, P; Palacio, I; Prieto, M; Redondo, A; Rodriguez, V; Rodriguez-Moreno, JF; Rubio, MJ; Santaballa, A; Taus, A; Vidal, L, 2023) |
| "Epithelial ovarian cancer remains the most devastating gynecologic cancer with drug resistance and rapid recurrence." | 1.43 | Inhibition of pregnane X receptor pathway contributes to the cell growth inhibition and apoptosis of anticancer agents in ovarian cancer cells. ( Hiramatsu, Y; Masuyama, H; Nakamura, K; Nobumoto, E, 2016) |
| "The erythromycin breath test is a valuable tool for measuring instantaneous CYP3A activity in vivo." | 1.30 | Predicting drug interactions in vivo from experiments in vitro. Human studies with paclitaxel and ketoconazole. ( Blake, DS; Collins, JM; Jamis-Dow, CA; Klecker, RW; Pearl, ML; Watkins, PB, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Garcia-Donas, J | 2 |
| Hurtado, A | 2 |
| Garrigos, L | 1 |
| Santaballa, A | 1 |
| Redondo, A | 1 |
| Vidal, L | 1 |
| Lainez, N | 1 |
| Guerra, E | 1 |
| Rodriguez, V | 1 |
| Cueva, J | 1 |
| Bover, I | 1 |
| Palacio, I | 1 |
| Rubio, MJ | 1 |
| Prieto, M | 1 |
| Lopez-Guerrero, JA | 2 |
| Rodriguez-Moreno, JF | 1 |
| Garcia-Casado, Z | 2 |
| Garcia-Martinez, E | 1 |
| Taus, A | 1 |
| de Castro, IP | 1 |
| Navarro, P | 1 |
| Grande, E | 2 |
| Liu, XJ | 1 |
| Lu, H | 1 |
| Sun, JX | 1 |
| Wang, SR | 1 |
| Mo, YS | 1 |
| Yang, XS | 1 |
| Shi, BK | 1 |
| Masuyama, H | 1 |
| Nakamura, K | 1 |
| Nobumoto, E | 1 |
| Hiramatsu, Y | 1 |
| Sedhom, R | 1 |
| Hu, S | 1 |
| Ohri, A | 1 |
| Infantino, D | 1 |
| Lubitz, S | 1 |
| La Rosa, S | 1 |
| Marando, A | 1 |
| Ghezzi, F | 1 |
| Colombo, P | 1 |
| Finzi, G | 1 |
| Capella, C | 1 |
| Albareda, J | 1 |
| Alemany, I | 1 |
| Camara, JC | 1 |
| Hernando, S | 1 |
| Donovan, JT | 1 |
| Otis, CN | 1 |
| Powell, JL | 1 |
| Cathcart, HK | 1 |
| Jamis-Dow, CA | 1 |
| Pearl, ML | 1 |
| Watkins, PB | 1 |
| Blake, DS | 1 |
| Klecker, RW | 1 |
| Collins, JM | 1 |
1 trial available for ketoconazole and Ovarian Neoplasms
| Article | Year |
|---|---|
Open-label phase II clinical trial of ketoconazole as CYP17 inhibitor in metastatic or advanced non-resectable granulosa cell ovarian tumors: the GREKO (GRanulosa Et KetOconazole) trial, GETHI 2011-03.
Topics: Enzyme Inhibitors; Female; Forkhead Transcription Factors; Granulosa Cells; Humans; Ketoconazole; Ov | 2023 |
7 other studies available for ketoconazole and Ovarian Neoplasms
| Article | Year |
|---|---|
Metabolic behavior prediction of pazopanib by cytochrome P450 (CYP) 3A4 by molecular docking.
Topics: Amino Acids; Antineoplastic Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug | 2016 |
Inhibition of pregnane X receptor pathway contributes to the cell growth inhibition and apoptosis of anticancer agents in ovarian cancer cells.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Ovarian Epithelial; | 2016 |
Symptomatic Cushing's syndrome and hyperandrogenemia in a steroid cell ovarian neoplasm: a case report.
Topics: Aged; Antineoplastic Agents, Hormonal; Cushing Syndrome; Disease Progression; Fatal Outcome; Female; | 2016 |
Cushing's syndrome due to a pancreatic neuroendocrine tumor metastatic to the ovaries: a clinicopathological description of a case.
Topics: ACTH Syndrome, Ectopic; Adult; Carcinoma, Neuroendocrine; Cushing Syndrome; Fatal Outcome; Female; H | 2011 |
Cytochrome P17 inhibition with ketoconazole as treatment for advanced granulosa cell ovarian tumor.
Topics: 14-alpha Demethylase Inhibitors; Adult; Antineoplastic Combined Chemotherapy Protocols; Base Sequenc | 2013 |
Cushing's syndrome secondary to malignant lipoid cell tumor of the ovary.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cushing Syndrome; Female; Humans; H | 1993 |
Predicting drug interactions in vivo from experiments in vitro. Human studies with paclitaxel and ketoconazole.
Topics: Antifungal Agents; Antineoplastic Agents, Phytogenic; Aryl Hydrocarbon Hydroxylases; Breath Tests; C | 1997 |